Us Bancorp \De\ Celldex Therapeutics, Inc. Transaction History
Us Bancorp \De\
- $75.6 Billion
- Q4 2024
A detailed history of Us Bancorp \De\ transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 509 shares of CLDX stock, worth $10,739. This represents 0.0% of its overall portfolio holdings.
Number of Shares
509
Previous 682
25.37%
Holding current value
$10,739
Previous $23,000
47.83%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CLDX
# of Institutions
197Shares Held
69.7MCall Options Held
960KPut Options Held
675K-
Wellington Management Group LLP Boston, MA8.98MShares$189 Million0.04% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.06MShares$107 Million8.11% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$99 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$81.9 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$79.2 Million1.82% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $987M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...